Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243503 · ClinicalTrials.gov registry record · Phase 2
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00243503 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 60 participants.
The verdict
NCT00243503, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in combination with trastuzumab and compare efficacy and safety.
Interventions
- DRUG SU011248/Trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00243503
The ClinicalTrials.gov registry entry for NCT00243503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SU011248/Trastuzumab is the first listed.
NCT00243503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00243503 about?
NCT00243503 is a clinical study titled "Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer". The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK i...
What is the current status of trial NCT00243503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-02. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00243503?
The interventions under investigation include: SU011248/Trastuzumab (DRUG).
Who is sponsoring clinical trial NCT00243503?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.